Public Event Detail
Arax Advisory Partners Has $30.94 Million Stock Position in Merck & Co., Inc. $MRK
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-06-14JPMJPMorgan ChaseAlpha Vantage Newsearnings
Event summary
Arax Advisory Partners reduced its stake in Merck & Co., Inc. by 31.5% in the fourth quarter, ending with 293,929 shares valued at $30.94 million. Despite the reduction, Merck reported strong first-quarter results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.85 per share. Analyst sentiment remains largely positive, with a "Moderate Buy" average rating and a target price of $128.18.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending